Amprius Swaps 7.1 Million Warrants for 2.7 Million Shares — Does the Dilution Math Actually Favor Existing Shareholders?

Shares of Amprius Technologies slid 4.1% to $17.14 as the battery maker finalized the pricing of a warrant exchange deal that lands more stock in investor hands now — but eliminates a much larger overhang down the road. The question is whether Wall Street is punishing the near-term dilution while undervaluing the long-term cleanup.

• The Company Is Issuing Fewer Shares Than Warrants Would Have Created. Amprius will issue 2,726,631 shares in exchange for 7,128,458 public warrants, resulting in 62% fewer shares issued than a physical exercise of the warrants.

Those warrants, originally issued in March 2022 when Amprius went public via a blank-check company, would have expired in September 2027. Had all warrants been exercised at $11.50 — well below the current price — the share count would have swollen by 7.1 million. Instead, existing shareholders absorb roughly 2.7 million new shares, a net savings of 4.4 million shares of future dilution.

• The Immediate Hit Stings, But the Math Is Straightforward. With approximately 141.6 million shares outstanding , the new issuance adds about 1.9% to the float. That's what the market is pricing in today. But the alternative — full warrant exercise — would have added roughly 5%. By paying a small price now, Amprius removes a persistent cloud that suppressed its stock's appeal to institutional buyers wary of hidden dilution.

• Analysts Are Still Raising Targets, Not Cutting Them. Northland raised its price target to $24 and Roth Capital to $22 , both after the warrant deal was announced. B. Riley also raised to $22 with a Buy rating. Those targets sit 28–40% above today's price, suggesting analysts view the capital-structure cleanup as accretive, not destructive.

• The Business Underneath Is Growing Fast Enough to Absorb It. Q1 2026 revenue hit $28.5 million, up 2.5x year-over-year , and gross margins reached 20%, with gross profit improving 343%.

Management is guiding for $125M+ in 2026 revenue and positive adjusted EBITDA — a profitability milestone that would make the 1.9% dilution a rounding error. The company also reported roughly $500 million in new U.S. defense purchase orders , giving its revenue pipeline real weight.

The bottom line: Amprius traded short-term pain for long-term clarity. Today's sell-off prices in the 2.7 million new shares but largely ignores the 4.4 million that will never hit the market. For a company approaching profitability with a half-billion-dollar defense backlog, that trade looks favorable.